Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.

Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849

Mapping and quantifying mammalian transcriptomes by RNA-Seq

Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696

Primer3—new capabilities and interfaces

Untergasser, A., Cutcutache, I., Kõressaar, T., Ye, J., Faircloth, B., Remm, M., & Rozen, S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,165

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049

<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool

Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Messenger RNA vaccines for cancer immunotherapy: progress promotes promise

Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 60

Engineering Versatile Bacteria‐Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy

Luo, Z., Cheng, X., Feng, B., Fan, D., Liu, X., Xie, R., Luo, T., Wegner, S. V., Ma, D., Chen, F., et al. (2024) · Advanced Science · doi:10.1002/advs.202400049 · Cited by 55

Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma

Effern, M., Glodde, N., Braun, M., Liebing, J., Boll, H. N., Yong, M. C. R., Bawden, E., Hinze, D., Konijnenberg, D., Daoud, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.007 · Cited by 55

Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence

Zhou, X., Qu, M., Tebon, P. J., Jiang, X., Wang, C., Xue, Y., Zhu, J., Zhang, S., Öklü, R., Sengupta, S., et al. (2020) · Advanced Science · doi:10.1002/advs.202001447 · Cited by 55

Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination

Tombácz, I., Weissman, D., & Pardi, N. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0872-2_2 · Cited by 55

Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA

Vlatkovic, I., Ludwig, J., Boros, G., Szabó, G. T., Reichert, J., Buff, M. C. R., Baiersdörfer, M., Reinholz, J., Mahiny, A. J., Şahin, U., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020328 · Cited by 53

mRNA vaccine designs for optimal adjuvanticity and delivery

Mochida, Y., & Uchida, S. (2024) · RNA Biology · doi:10.1080/15476286.2024.2333123 · Cited by 57

In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cells

Li, Y., Tian, Y., Li, C., Fang, W., Li, X., Jing, Z., Yang, Z., Zhang, X., Huang, Y., Gong, J., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102518 · Cited by 57

Neoantigen Vaccines Pass the Immunogenicity Test

Linette, G. P., & Carreno, B. M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.007 · Cited by 54

Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines

Wu, J., Li, W., Chen, P., Zhang, B., Hu, H., Li, Q., Zhao, L., Chen, Y., Zhao, Y., & Li, Y. (2018) · Chemical Communications · doi:10.1039/c8cc04860f · Cited by 56

New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation

Curran, M. A., & Glisson, B. S. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050217-121900 · Cited by 56

Tumor-Specific T Cell Activation in Malignant Brain Tumors

Mohme, M., & Neidert, M. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00205 · Cited by 55

Emerging Strategies in TCR-Engineered T Cells

Fang, W., Cheng, X., Xue, J. Z., & Xue, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850358 · Cited by 58

Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade

Miyai, Y., Sugiyama, D., Hase, T., Asai, N., Taki, T., Nishida, K., Fukui, T., Chen-Yoshikawa, T. F., Kobayashi, H., Mii, S., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101230 · Cited by 55

Targeting strategies for mRNA delivery

Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55

Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types

Gurung, H. R., Heidersbach, A. J., Darwish, M., Chan, P. P. F., Li, J., Beresini, M. H., Zill, O. A., Wallace, A., Tong, A.-J., Hascall, D., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01945-y · Cited by 59

Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics

Prajapati, R. N., Bhushan, B., Singh, K., Chopra, H., Kumar, S., Agrawal, M., Pathak, D., Chanchal, D. K., & Kant, L. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010275850240102105033 · Cited by 62

Recent advances in lung cancer research: unravelling the future of treatment

Bertolaccini, L., Casiraghi, M., Uslenghi, C., Maiorca, S., & Spaggiari, L. (2024) · Updates in Surgery · doi:10.1007/s13304-024-01841-3 · Cited by 55

Accounting for proximal variants improves neoantigen prediction

Hundal, J., Kiwala, S., Feng, Y.-Y., Liu, C. J., Govindan, R., Chapman, W. C., Uppaluri, R., Swamidass, S. J., Griffith, O. L., Mardis, E. R., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0283-9 · Cited by 55

The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice

Sultan, H., Kumai, T., Nagato, T., Wu, J., Salazar, A. Μ., & Celis, E. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-02294-5 · Cited by 53

Design of in vitro Transcribed mRNA Vectors for Research and Therapy

Tusup, M., French, L. E., Matos, M. D., Gatfield, D., Kündig, T. M., & Pascolo, S. (2019) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2019.391 · Cited by 55

Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens

Zhang, R., Tang, L., Tian, Y., Xiao, J., Hu, Q., Zhou, B., Zhenyu, D., Xu, H., & Yang, L. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119852 · Cited by 53

Personalized cancer vaccination in head and neck cancer

Shibata, H., Zhou, L., Xu, N., Egloff, A. M., & Uppaluri, R. (2020) · Cancer Science · doi:10.1111/cas.14784 · Cited by 54

mRNA vaccines: a new era in vaccine development

Chandra, S., Wilson, J. C., Good, D. M., & Wei, M. Q. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.043987 · Cited by 58

COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy

Novelli, G., Biancolella, M., Mehrian‐Shai, R., Colona, V. L., Brito, A. F., Grubaugh, N. D., Vasiliou, V., Luzzatto, L., & Reichardt, J. K. V. (2021) · Human Genomics · doi:10.1186/s40246-021-00326-3 · Cited by 51

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 67

Acquired resistance to cancer immunotherapy

Draghi, A., Chamberlain, C. A., Furness, A. J. S., & Donia, M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0692-y · Cited by 51

MHCAttnNet: predicting MHC-peptide bindings for MHC alleles classes I and II using an attention-based deep neural model

Venkatesh, G. S., Grover, A., Srinivasaraghavan, G., & Rao, S. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa479 · Cited by 55

Targeting Tumor‐Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies

Lu, L., Jiang, J., Zhan, M., Zhang, H., Wang, Q., Sun, S., Guo, X., Yin, H., Wei, Y., Li, S., et al. (2020) · Hepatology · doi:10.1002/hep.31502 · Cited by 52

The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview

Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 55

Breaking Bottlenecks for the TCR Therapy of Cancer

Gaissmaier, L., Elshiaty, M., & Christopoulos, P. (2020) · Cells · doi:10.3390/cells9092095 · Cited by 52

Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development

Liang, J., & Zhao, X. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0004 · Cited by 53

Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics

de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51

Considerations for personalized neoantigen vaccination in Malignant glioma

Dunn, G. P., Sherpa, N. D., Manyanga, J., & Johanns, T. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114312 · Cited by 51

Engineering neoantigen vaccines to improve cancer personalized immunotherapy

Liu, Z., Lv, J., Dang, Q., Liu, L., Weng, S., Wang, L., Zhou, Z., Kong, Y., Li, H., Han, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.76281 · Cited by 52

Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry

Phulphagar, K. M., Ctortecka, C., Jácome, A. S. V., Klaeger, S., Verzani, E. K., Hernandez, G. M., Udeshi, N. D., Clauser, K. R., Abelin, J. G., & Carr, S. A. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100563 · Cited by 49

IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing

Pan, Y., Phillips, J. W., Zhang, B. D., Noguchi, M., Kutschera, E., McLaughlin, J., Nesterenko, P. A., Mao, Z., Bangayan, N. J., Wang, R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221116120 · Cited by 50

Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy

Wilhelmy, C., Keil, I. S., Uebbing, L., Schroer, M. A., Franke, D., Nawroth, T., Barz, M., Şahin, U., Haas, H., Diken, M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082068 · Cited by 51

Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification

Tretter, C., Krätzig, N. D. A., Pecoraro, M., Lange, S., Seifert, P., von Frankenberg, C., Untch, J., Zuleger, G., Wilhelm, M., Zolg, D. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39570-7 · Cited by 49

High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions

Blaha, D. T., Anderson, S. D., Yoakum, D. M., Hager, M. V., Zha, Y., Gajewski, T. F., & Kranz, D. M. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0395 · Cited by 49

Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma

Vitiello, M., Evangelista, M., Lascio, N. D., Kusmic, C., Massa, A., Orso, F., Sarti, S., Marranci, A., Rodzik, K., Germelli, L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0681-1 · Cited by 53

Polydopamine-Based “Four-in-One” Versatile Nanoplatforms for Targeted Dual Chemo and Photothermal Synergistic Cancer Therapy

Liu, G., Gao, N., Zhou, Y., Nie, J., Cheng, W., Luo, M., Mei, L., Zeng, X., & Deng, W. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11100507 · Cited by 51

TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopes

Zhang, G., Chitkushev, L. T., Olsen, L. R., Keskin, D. B., & Brusić, V. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-03962-7 · Cited by 56

mRNA vaccines in the prevention and treatment of diseases

Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 54

Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development

Huber, F., & Bassani‐Sternberg, M. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01208-8 · Cited by 57

RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade

Ruzicka, M., König, L. M., Formisano, S., Boehmer, D. F. R., Vick, B., Heuer, E.-M., Meinl, H., Kocheise, L., Zeitlhoefler, M., Ahlfeld, J., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0639-x · Cited by 50

T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies

Janelle, V., Rulleau, C., Testa, S. D., Carli, C., & Delisle, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00276 · Cited by 52

Immune Therapy Opportunities in Ovarian Cancer

Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280539 · Cited by 52

Comparative study of α-helical and β-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes

Wu, Y., Kelly, S. H., Sanchez-Perez, L. A., Sampson, J. H., & Collier, J. H. (2020) · Biomaterials Science · doi:10.1039/d0bm00521e · Cited by 54

Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance

Nagy, N. A., de Haas, A. M., Geijtenbeek, T. B. H., van Ree, R., Tas, S. W., van Kooyk, Y., & de Jong, E. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674048 · Cited by 49

Non-Viral Vectors for Delivery of Nucleic Acid Therapies for Cancer

Kanvinde, S., Kulkarni, T. A., Deodhar, S., Bhattacharya, D. S., & Dasgupta, A. (2022) · BioTech · doi:10.3390/biotech11010006 · Cited by 55

The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy

Ravindran, S., Rasool, S., & Maccalli, C. (2019) · Cancer Microenvironment · doi:10.1007/s12307-019-00233-1 · Cited by 49

Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy

Richard, G., Princiotta, M. F., Bridon, D. P., Martin, W. D., Steinberg, G. D., & Groot, A. S. D. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2012456 · Cited by 49

An Ionizable Lipid Material with a Vitamin E Scaffold as an mRNA Vaccine Platform for Efficient Cytotoxic T Cell Responses

Oyama, R., Ishigame, H., Tanaka, H., Tateshita, N., Itazawa, M., Imai, R., Nishiumi, N., Kishikawa, J.-I., Kato, T., Anindita, J., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c02251 · Cited by 49

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

Gravel, N. H., Nelde, A., Bauer, J., Mühlenbruch, L., Schroeder, S. M., Neidert, M. C., Scheid, J., Lemke, S., Dubbelaar, M. L., Wacker, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42692-7 · Cited by 51

Recent advances and perspectives on the development of circular RNA cancer vaccines

Gong, Z., Hu, W., Zhou, C., Guo, J., Yang, L., & Wang, B. (2025) · npj Vaccines · doi:10.1038/s41541-025-01097-x · Cited by 55

The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy

Kärpänen, T., & Olweus, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01718 · Cited by 50

Targeting Head and Neck Cancer by Vaccination

Wang, C., Dickie, J., Sutavani, R. V., Pointer, C., Thomas, G. J., & Savelyeva, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00830 · Cited by 51

Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy

Hazama, S., Tamada, K., Yamaguchi, Y., Kawakami, Y., & Nagano, H. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12180 · Cited by 50

Novel Biomarkers for Personalized Cancer Immunotherapy

Shindo, Y., Hazama, S., Tsunedomi, R., Suzuki, N., & Nagano, H. (2019) · Cancers · doi:10.3390/cancers11091223 · Cited by 49

A liposomal RNA vaccine inducing neoantigen-specific CD4 + T cells augments the antitumor activity of local radiotherapy in mice

Salomon, N., Vascotto, F., Selmi, A., Vormehr, M., Quinkhardt, J., Bukur, T., Schrörs, B., Löewer, M., Diken, M., Türeci, Ö., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771925 · Cited by 49

Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites

Morisaki, T., Hikichi, T., Onishi, H., Morisaki, T., Kubo, M., Hirano, T., Yoshimura, S., Kiyotani, K., & Nakamura, Y. (2020) · Immunological Investigations · doi:10.1080/08820139.2020.1778721 · Cited by 48

N 6 ‐methyladenosine Steers RNA Metabolism and Regulation in Cancer

Dong, S., Wu, Y., Liu, Y., Weng, H., & Huang, H. (2021) · 癌症：英文版 · doi:10.1002/cac2.12161 · Cited by 48

Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets

Liu, G., Carter, B., & Gifford, D. K. (2020) · Cell Systems · doi:10.1016/j.cels.2020.11.010 · Cited by 48

Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors

Çuburu, N., Bialkowski, L., Pontejo, S. M., Sethi, S. K., Bell, A. T. F., Kim, R., Thompson, C. D., Lowy, D. R., & Schiller, J. T. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116738119 · Cited by 48

The immune-related role of beta-2-microglobulin in melanoma

Wang, C., Wang, Z., Yao, T., Zhou, J., & Wang, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.944722 · Cited by 52

The role of CD4+ T cells in tumor and chronic viral immune responses

Xie, L., Fang, J., Yu, J., Zhang, W., He, Z., Ye, L., & Wang, H. (2023) · MedComm · doi:10.1002/mco2.390 · Cited by 54

mRNA vaccines in the context of cancer treatment: from concept to application

Fu, Q., Zhao, X., Hu, J., Jiao, Y., Yan, Y., Pan, X., Wang, X., & Jiao, F. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06033-6 · Cited by 59

Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC

Şahin, U., Schmidt, M., Derhovanessian, E., Cortini, A., Vogler, I., Omokoko, T., Godehardt, E., Attig, S., Newrzela, S., GRUTZNER, J., et al. (2026) · Nature · doi:10.1038/s41586-025-10004-2 · Cited by 50

Shared Neoantigens: Ideal Targets for Off-The-Shelf Cancer Immunotherapy

Zhao, W., Wu, J., Chen, S., & Zhou, Z. M. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0184 · Cited by 49

Progress in Neoantigen Targeted Cancer Immunotherapies

Han, X., Ma, X., Li, Y., Wei, Y.-Q., Peng, Y., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00728 · Cited by 49

Large scale, robust, and accurate whole transcriptome profiling from clinical formalin-fixed paraffin-embedded samples

Newton, Y., Sedgewick, A. J., Cisneros, L. H., Golovato, J., Johnson, M., Szeto, C. W., Rabizadeh, S., Sanborn, Z., Benz, S. C., & Vaske, C. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-74483-1 · Cited by 48

Dendrimers for cancer immunotherapy: Avidity‐based drug delivery vehicles for effective anti‐tumor immune response

Rawding, P. A., Bu, J., Wang, J., Kim, D., Drelich, A. J., Kim, Y. S., & Hong, S. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1752 · Cited by 50

Messenger RNA-Based Therapeutics and Vaccines: What’s beyond COVID-19?

Li, D., Liu, C., Li, Y., Tenchov, R., Sasso, J. M., Zhang, D., Li, D., Zou, L., Wang, X., & Zhou, Q. A. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00047 · Cited by 50

Challenges towards the realization of individualized cancer vaccines

Türeci, Ö., Löwer, M., Schrörs, B., Lang, M., Tadmor, A. D., & Şahin, U. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0266-2 · Cited by 49

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design

Cai, W., Zhou, D., Wu, W., Tan, W. L., Wang, J., Zhou, C., & Lou, Y. (2018) · BMC Genomics · doi:10.1186/s12864-018-4958-5 · Cited by 47

Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor

Fontana, F., Fusciello, M., Groeneveldt, C., Capasso, C., Chiaro, J., Feola, S., Liu, Z., Mäkilä, E. M., Salonen, J., Hirvonen, J. J., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b09613 · Cited by 47

An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines

Ott, P. A., Dotti, G., Yee, C., & Goff, S. L. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238001 · Cited by 48

Non-covalent glycosylated gold nanoparticles/peptides nanovaccine as potential cancer vaccines

Zeng, L., Liao, Z., Li, W., Yuan, Q., Wu, P., Gu, Z., Liu, Z., & Liao, G. (2019) · Chinese Chemical Letters · doi:10.1016/j.cclet.2019.10.015 · Cited by 47

Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review

Bouzid, R., Peppelenbosch, M. P., & Buschow, S. I. (2020) · Cancers · doi:10.3390/cancers12051121 · Cited by 46

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer

Zou, X.-L., Li, X., Ke, H., Zhang, G., Tang, Q., Yuan, J., Zhou, C.-J., Zhang, J., Zhang, R., & Chen, W.-Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689076 · Cited by 48

Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy

Okada, M., Shimizu, K., & Fujii, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052594 · Cited by 50

Neoantigen cancer vaccines: a new star on the horizon

Li, X., You, J., Hong, L., Liu, W., Guo, P., & Hao, X. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0395 · Cited by 53

Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum

Ingels, J., Cock, L. D., Stevens, D., Mayer, R. L., Théry, F., Sanchez, G. S., Vermijlen, D., Weening, K., Smet, S. D., Lootens, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101516 · Cited by 49

Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors

Wang, X., Wang, W., Zou, S., Xu, Z., Cao, D., Zhang, S., Wei, M., Zhan, Q., Wen, C., Li, F., et al. (2024) · Cell Research · doi:10.1038/s41422-024-00990-9 · Cited by 46

Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment

Baharom, F., Hermans, D., Delamarre, L., & Seder, R. A. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01091-9 · Cited by 47

Apolipoprotein Fusion Enables Spontaneous Functionalization of mRNA Lipid Nanoparticles with Antibody for Targeted Cancer Therapy

Park, W., Choi, J., Hwang, J., Kim, S. H., Kim, Y., Shim, M. K., Park, W., Yu, S., Jung, S., Yang, Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c16562 · Cited by 47

Complex neural-immune interactions shape glioma immunotherapy

Song, K.-W., Lim, M. K., & Monje, M. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.017 · Cited by 50

Aluminum hydroxide colloid vaccine encapsulated in yeast shells with enhanced humoral and cellular immune responses

Liu, H., Jia, Z., Yang, C., Song, M. L., Jing, Z., Zhao, Y., Wu, Z., Zhao, L., Wei, D., Yin, Z., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.014 · Cited by 45

Peptide Delivery Systems for Cancer Vaccines

He, X., Abrams, S. I., & Lovell, J. F. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800060 · Cited by 45

Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity

Lybaert, L., Vermaelen, K. Y., Geest, B. G. D., & Nuhn, L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.009 · Cited by 46

Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients

Petrizzo, A., Tagliamonte, M., Mauriello, A., Costa, V., Aprile, M., Esposito, R., Caporale, A., Luciano, A., Arra, C., Tornesello, M. L., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1662-9 · Cited by 46

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers

Yang, B., Liu, T., Qu, Y., Liu, H., Zheng, S. G., Cheng, B., & Sun, J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00563 · Cited by 47

Technology Opportunity Analysis: Combining SAO Networks and Link Prediction

Han, X., Zhu, D., Wang, X., Li, J., & Qiao, Y. (2019) · IEEE Transactions on Engineering Management · doi:10.1109/tem.2019.2939175 · Cited by 46

High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy

Mauriello, A., Zeuli, R., Cavalluzzo, B., Petrizzo, A., Tornesello, M. L., Buonaguro, L., Ceccarelli, M., Tagliamonte, M., & Buonaguro, L. (2019) · Cancers · doi:10.3390/cancers11121824 · Cited by 50

INeo‐Epp: A Novel T‐Cell HLA Class‐I Immunogenicity or Neoantigenic Epitope Prediction Method Based on Sequence‐Related Amino Acid Features

Wang, G., Wan, H., Jian, X., Li, Y., Ouyang, J., Tan, X., Zhao, Y., Lin, Y., & Xie, L. (2020) · BioMed Research International · doi:10.1155/2020/5798356 · Cited by 47

Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal

Bianchi, V., Harari, A., & Coukos, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01215 · Cited by 47

Cationic Nanoparticle-Based Cancer Vaccines

Heuts, J., Jiskoot, W., OSSENDORP, F. A., & van der Maaden, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050596 · Cited by 46

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma

Bao, R., Spranger, S., Hernandez, K. M., Zha, Y., Pytel, P., Luke, J. J., Gajewski, T. F., Volchenboum, S. L., Cohn, S. L., & Desai, A. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002417 · Cited by 45

Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses

Wu, Y., Wen, H., Bernstein, Z. J., Hainline, K. M., Blakney, T. S., Congdon, K. L., Snyder, D. J., Sampson, J. H., Sanchez-Perez, L. A., & Collier, J. H. (2022) · Science Advances · doi:10.1126/sciadv.abm7833 · Cited by 48

An immunogenic personal neoantigen vaccine for patients with melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936

Abstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

Miller, M., Loquai, C., Kloke, B., Attig, S., Bidmon, N., Bolte, S., Bukur, V., Derhovanessian, E., Diekmann, J., Filbry, A., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct022

Precision T-cell therapy targets tumours

Melief, C. J. M. (2017) · Nature · doi:10.1038/nature23093 · Cited by 28

Abstract PR02: A personalized neoantigen vaccine in patients with high risk melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Fritsch, E. F., Hacohen, N., & Wu, C. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.imm2016-pr02

Personalized melanoma vaccines

Kelly, P. N. (2017) · Science · doi:10.1126/science.357.6353.769-b